Learn

In this seminar, Dr Richard Scolaro outlines the rationale behind the European Medicines Agency's (EMA) December 2022 recommendation to revoke the EU marketing authorisations for pholcodine-containing medications. In February 2023, the Australian Register of Therapeutic Goods (ARTG) also cancelled fifty-five products containing pholcodine. In a separate action, The New Zealand Medicines and Medical Devices Safety Authority (MEDsafe) rescinded consent to the distribution of pholcodine-containing medicines in January 2024.

Learning Outcomes

1. Evaluate the rationale behind the European Medicine Agency's (EMA) December 2022 recommendation to revoke EU marketing authorisations for pholcodine-containing medications, with reference to the ALPHO study and supporting evidence on associated anaphylactic risks
2. Assess the rationale behind the Australian Register of Therapeutic Goods' (ARTG) February 2023 cancellation of 55 pholcodine-containing medicine, citing the increased risks of anaphylactic reactions to neuromuscular blocking agents
3. Appraise some of the critical steps involved in the effective management of anaphylaxis. 

Details

ASANSC 2023 Melbourne - Seminars Series for Anaesthetists.                 

Authors: Dr Richard Scolaro

This activity is accepted by CPD Home as a Domain 1: Educational Activity in alignment with the CPD Program Guide.

Disclaimer: Please note, once you click 'Enrol now' you will be leaving the AMA’s CPD Home website and entering a third-party website.